The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...
Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart does not fill with blood properly. In HFpEF, the heart can pump normally, but the heart is stiff and cannot ...
Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, ...
7d
Distinct metabolic signature found in patients with heart failure with preserved ejection fraction
What exactly happens in the hearts of patients with heart failure with preserved ejection fraction (HFpEF)—and how can this ...
The American Heart Association, a relentless force changing the future of health for everyone everywhere, is launching a new initiative to improve in-hospital care for people with heart failure with ...
Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results